Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) agreed to acquire Nanyue Biopharming Corporation Ltd. from group of shareholders for CNY 4.2 billion on March 25, 2025. A cash consideration of CNY 4.2 billion will be paid by Shanghai RAAS Blood Products Co., Ltd. As part of consideration, CNY 4.2 billion is paid towards common equity of Nanyue Biopharming Corporation Ltd.
As of September 30, 2024, Nanyue Biopharming Corporation Ltd. reported total assets of CNY 1.37 billion and total common equity of CNY 838.53 million.
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
